ATE403647T1 - Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden - Google Patents

Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden

Info

Publication number
ATE403647T1
ATE403647T1 AT01998144T AT01998144T ATE403647T1 AT E403647 T1 ATE403647 T1 AT E403647T1 AT 01998144 T AT01998144 T AT 01998144T AT 01998144 T AT01998144 T AT 01998144T AT E403647 T1 ATE403647 T1 AT E403647T1
Authority
AT
Austria
Prior art keywords
receptor ligands
indoline derivatives
indoline
derivatives
ligands
Prior art date
Application number
AT01998144T
Other languages
English (en)
Inventor
Jonathan Mark Bentley
James Edward Paul Davidson
Howard Langham Mansell
Nathaniel Julius Thomas Monck
Original Assignee
Hoffmann La Roche
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE403647T1 publication Critical patent/ATE403647T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT01998144T 2000-10-16 2001-10-12 Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden ATE403647T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00122539 2000-10-16

Publications (1)

Publication Number Publication Date
ATE403647T1 true ATE403647T1 (de) 2008-08-15

Family

ID=8170101

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998144T ATE403647T1 (de) 2000-10-16 2001-10-12 Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden

Country Status (15)

Country Link
US (1) US6479534B1 (de)
EP (1) EP1328515B1 (de)
JP (1) JP4047723B2 (de)
KR (1) KR100545435B1 (de)
CN (1) CN100334076C (de)
AR (1) AR038762A1 (de)
AT (1) ATE403647T1 (de)
AU (2) AU2167002A (de)
BR (1) BR0114708A (de)
CA (1) CA2422698C (de)
DE (1) DE60135239D1 (de)
ES (1) ES2311563T3 (de)
MX (1) MXPA03003246A (de)
WO (1) WO2002044152A1 (de)
ZA (1) ZA200302516B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454383T1 (de) 2002-06-19 2010-01-15 Biovitrum Ab Publ Neue verbindungen, deren verwendung und herstellung
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
US7081696B2 (en) 2004-08-12 2006-07-25 Exro Technologies Inc. Polyphasic multi-coil generator
EP1792629A4 (de) 2004-08-25 2010-08-25 Takeda Pharmaceutical Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
TW200640931A (en) 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (de) 2005-05-30 2016-03-30 Msd K.K. Neues piperidinderivat
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP2330125A3 (de) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybridpolypeptide mit auswählbaren Eigenschaften
EP1921065B1 (de) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridonderivat
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
KR101318127B1 (ko) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 아자 치환된 스피로 유도체
EP2018863B9 (de) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Kondensierte, heterocyclische Verbindung und ihre Verwendung
EA201200033A1 (ru) 2006-06-08 2012-05-30 Эксро Технолоджис Инк. Устройство электрического генератора или двигателя
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
WO2008047544A1 (fr) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Dérivé diarylcétimine
WO2008039087A2 (en) * 2006-09-29 2008-04-03 Auckland Uniservices Limited Indoline derivatives and uses thereof
TW200823187A (en) * 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
MY154869A (en) 2007-01-16 2015-08-14 Ipintl Llc Composition for treating metabolic syndrome
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
EP2264026A4 (de) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridinderivate
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
EP2319841A1 (de) 2008-07-30 2011-05-11 Msd K.K. (5-gliedriges)-(5-gliedriges) oder (5-gliedriges)-(6-gliedriges) kondensiertes ringcycloalkylaminderivat
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102272103B (zh) 2008-10-30 2015-10-21 默沙东公司 异烟酰胺食欲素受体拮抗剂
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (de) 2008-12-16 2011-10-26 Schering Corporation Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
EP2510949A4 (de) 2009-12-11 2013-11-13 Astellas Pharma Inc Therapeutikum für fibromyalgie
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
CA2828346C (en) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
RU2021109549A (ru) 2014-08-29 2021-05-13 Тес Фарма С.Р.Л. ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
MX2019012806A (es) 2017-05-23 2020-01-20 Dpm Tech Inc Configuracion de sistema de control de bobina variable, aparato y metodo.
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
AU2019385644A1 (en) 2018-11-20 2021-06-03 Tes Pharma S.R.L. Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase
EP3924058A1 (de) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl-pyrrolidinorexinrezeptor-agonisten
CA3137550C (en) 2019-04-23 2024-05-21 Dpm Technologies Inc. Fault tolerant rotating electric machine
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4171736A4 (de) 2020-06-27 2024-07-03 Crescenta Biosciences Neuartige verbindungen zur modulation des zellmetabolismus und verwendungen davon
IL300610A (en) 2020-08-18 2023-04-01 Merck Sharp ַ& Dohme Llc Bicycloheptane pyrrolidine compounds are orexin receptor agonists
WO2022232904A1 (en) 2021-05-04 2022-11-10 Exro Technologies Inc. Battery control systems and methods
JP2024518405A (ja) 2021-05-13 2024-05-01 エクスロ テクノロジーズ インク． 多相電気機械のコイルを駆動する方法及び装置

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2541211A (en) 1948-10-15 1951-02-13 Searle & Co Tertiary-aminoalkyl-tetrahydrocarbazoles
US2687414A (en) 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
DE930988C (de) 1953-01-01 1955-07-28 Bayer Ag Verfahren zur Herstellung von basisch alkylierten Tetrahydrocarbazolen oder Indolen
US3142678A (en) 1962-01-09 1964-07-28 American Home Prod Amino substituted penthienoindoles
US3663567A (en) * 1970-12-04 1972-05-16 Sandoz Ag N-substituted cycloalkanoindoles
GB1418703A (en) * 1973-06-02 1975-12-24 Pfizer Ltd 3-alkyl-9-substituted-1,2,3,4-tetrahydrocarbazoles
GB1432649A (de) 1973-09-07 1976-04-22 Ici Ltd
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
TW270114B (de) * 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
WO1998030548A1 (fr) 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
PT1105122E (pt) 1998-08-14 2005-08-31 Hoffmann La Roche Composicoes farmaceuticas que contem inibidores de lipase
BR9912979B1 (pt) 1998-08-14 2010-09-21 composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii

Also Published As

Publication number Publication date
AU2002221670B2 (en) 2006-11-02
ZA200302516B (en) 2004-06-30
ES2311563T3 (es) 2009-02-16
EP1328515A1 (de) 2003-07-23
KR20030048437A (ko) 2003-06-19
AU2167002A (en) 2002-06-11
EP1328515B1 (de) 2008-08-06
US20020183349A1 (en) 2002-12-05
AR038762A1 (es) 2005-01-26
MXPA03003246A (es) 2003-06-06
CN1630636A (zh) 2005-06-22
WO2002044152A1 (en) 2002-06-06
DE60135239D1 (de) 2008-09-18
JP2004527467A (ja) 2004-09-09
BR0114708A (pt) 2003-07-01
KR100545435B1 (ko) 2006-01-24
CA2422698A1 (en) 2002-06-06
CA2422698C (en) 2009-12-15
US6479534B1 (en) 2002-11-12
CN100334076C (zh) 2007-08-29
JP4047723B2 (ja) 2008-02-13

Similar Documents

Publication Publication Date Title
ATE403647T1 (de) Indolinderivate und deren verwendung als 5-ht2 rezeptor liganden
DE60001840D1 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
ATE369368T1 (de) Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
ATE280757T1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE514676T1 (de) Ionisierbare indolinon derivate und deren verwendung als ptk liganden
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE277905T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE60112607T2 (de) 3-arylindolderivate und deren verwendung als cb2-rezeptoragonisten
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60107221D1 (de) Indolin-2-on derivate und deren verwendung als liganden der ocytocin rezeptoren
ATE398108T1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
DE69925730D1 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
ATE269326T1 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
ATE306470T1 (de) Kondensierte indolinderivate und deren verwendung als 5ht, insbesondere 5ht2c, rezeptor liganden
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE50001729D1 (de) N-(indolcarbonyl-)piperazinderivate als 5-ht2a-rezeptor liganden
ATE280158T1 (de) 3-phenylpyridinderivative und deren verwendung als nk-1 rezeptorantagonisten
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE50105955D1 (de) Indol-3-yl-derivate und deren verwendung als integrin-inhibitoren
ATE267192T1 (de) 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a
ATE340784T1 (de) Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
ATE252079T1 (de) Indolderivate und deren verwendung als 5ht2a liganden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328515

Country of ref document: EP

REN Ceased due to non-payment of the annual fee